Aim Polymorphisms in the promoter region of the -fibrinogen gene are associated with increased plasma fibrinogen levels. We investigated whether the distribution of the C148T polymorphism is associated with an increase in cardiovascular risk.
Introduction
Fibrinogen is both a clotting factor and an acute phase reactant which plays a key role in thrombotic events. Increased plasma levels of fibrinogen have been associated with an increased risk for vascular events including myocardial infarction, stroke and venous thromboembolism [1] [2] [3] . The rate-limiting step in fibrinogen formation is the synthesis of the -polypeptide chain [4] . This in turn is regulated by a -fibrinogen promoter located on chromosome 4.
A C-T mutation at nucleotide position 148 of the -fibrinogen promoter gene is associated with increased plasma fibrinogen levels [5] . This polymorphism is in complete linkage disequilibrium with the G-A mutation at nucleotide position 455 [6] [7] [8] . The significance of the C148T (or G455A) mutation in determining vascular risk, however, remains unclear. The presence of the T allele has been associated with angiographic severity of atherosclerosis in postmyocardial infarction patients [7] . The Austrian Stroke Prevention Study group found that the TT genotype was a significant predictor of carotid atherosclerosis, with an odds ratio of 6·17 by multivariable analysis [9] . The AA genotype has also been associated with risk of ischaemic stroke in a study of hypertensive Japanese patients [10] and with risk of coronary artery disease in Chinese diabetics (odds ratio 4·19) [11] . A large cross-sectional study in Denmark, however, failed to find an association between the -fibrinogen promoter genotype and the risk of coronary artery disease [12] and null data have also been reported from the ECTIM population and recently from the Leiden group [13, 14] . Further complicating this issue, a recent report from the Edinburgh Artery Study associated the AA genotype with a twofold increase in risk of developing peripheral vascular disease but there was no link with coronary artery disease [15] . Thus controversy remains as to the role of polymorphisms in the -fibrinogen promoter gene in determining vascular risk. We sought, therefore, to investigate whether the presence of the 148T allele was associated with an increased risk of myocardial infarction, stroke and venous thromboembolism among a large cohort of initially healthy men who were prospectively observed for the occurrence of cardiovascular events.
Methods
We used a nested, case-control study design within the Physicians' Health Study -a randomized, doubleblind, placebo-controlled trial of aspirin and -carotene in the primary prevention of cardiovascular disease and cancer [16] . Men aged 40-84 years, with no history of myocardial infarction, stroke, transient ischaemic attack or cancer were randomly assigned in a 2 2 factorial design to one of four treatments: 325 mg of aspirin on alternate days, 50 mg of -carotene on alternate days, both drugs, or neither. All participants were followed for the occurrence of myocardial infarction, stroke, and venous thromboembolism (deep venous thrombosis or pulmonary embolism).
A sample of blood sufficient for DNA analysis was provided by each of the 14 916 men enrolled at the beginning of the study. The methods used to separate, store and recover DNA from these baseline samples have been previously reported [17] . Cases were defined as participants who provided a baseline blood sample and had a first myocardial infarction, stroke or venous thromboembolism during follow-up. Control subjects were randomly selected from those study participants who provided baseline blood specimens and who remained free of reported cardiovascular disease. Each case was matched with one control on the basis of length of follow-up (6-month intervals), age (within 2 years), and smoking status (past, current or never). All study participants also provided information on cardiovascular risk factors at baseline. Overall, 751 pairs of cases and control subjects were included in this analysis; these men were followed for a mean period of 8·6 years.
Each reported end-point was confirmed by a detailed review of hospital records, death certificates and autopsy reports by a committee of physicians using pre-specified standard criteria. The diagnosis of myocardial infarction required the presence of symptoms plus either increased cardiac enzyme levels or characteristic changes on electrocardiography. The diagnosis of stroke required a new focal neurological deficit and symptoms and signs that persisted for longer than 24 h; confirmatory computer tomography scans were available in more than 95% of cases. The diagnosis of venous thrombosis was considered to be confirmed when there was documentation of a positive venographic study or a positive ultrasonographic study. A diagnosis of pulmonary embolism required a positive angiogram or a completed ventilation-perfusion scan showing at least two segmental perfusion defects without ventilation defects.
A 362 base pair fragment of the 5 region of the gene for -fibrinogen (positions 214-575 of the GenBank sequence M 64983.1) was amplified by polymerase chain reaction from 50 ng of genomic DNA reaction using 300 nmol . l 1 each of the sense primer and the reverse primer. The sequence of the sense primer used was 5 -CCTAACTTCCCATCATTTTGTCCAAT TAA-3 and that of the reverse primer was 5 -TGTC GTTGACACCTTGGGACTTAACTAG-3 . Amplification consisted of 36 cycles (denaturation at 95 C for 15 s, annealing at 53 C for 45 s, and extension at 72 C for 30 s) in the presence of 200 mol . l 1 deoxynucleotide triphosphates, 2 · 5 mmol . l 1 magnesium chloride, and 0·15 units of Taq DNA polymerase.
Subsequent digestion with the restriction endonuclease Hind III (recognition sequence AAGCTT) resulted in fragments of 97 base pairs and 265 base pairs for the more common C allele ( 148C), but not for the T allele ( 148T). Genotypes were scored blinded as to case-control status.
Statistical analysis
Means and proportions for baseline cardiovascular risk factors were calculated for cases and controls. Differences in means were tested by the paired Student's t-test, and differences in proportions by the chi-squared test. The genotype distributions and allele frequencies in the case and control groups were compared by chi-squared analysis. Relative risks for thrombosis associated with each genotype were calculated by means of logistic regression models that controlled for randomized treatment assignment. Adjusted relative risks were calculated by further logistic regression models that controlled for randomized treatment assignment and the matching variables of age and smoking status as well as for traditional cardiovascular risk factors. All regression analyses controlled for the treatment assignments and all P values are two-tailed.
Results
The baseline characteristics of the men who developed myocardial infarction, stroke or venous thromboembolism during follow-up and those who remained free of
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cardiovascular disease are shown in Table 1 . As expected, the subjects who had myocardial infarction and stroke during follow-up had a higher prevalence of conventional risk factors at baseline than controls.
Among 751 controls who remained free of reported cardiovascular disease during follow-up, the T allele frequency was 21·5% (Table 2 ), a finding consistent with studies in other European and Caucasian populations of the C148T (or G455A) polymorphisms [5, 7, 18] . There were no differences in the genotype distribution or allele frequencies between the case and control subjects in analyses that included all cases (P=0·7 for genotype distribution, P=0·4 for allele frequency) or in subgroup analyses for men who developed myocardial infarction (P=0·8, 0·5), stroke (P=0·2, 0·2) or venous thromboembolism (P=0·2, 0·1; Table 2 ). Overall, the risk of any vascular event among men heterozygous and homozygous for T compared with men homozygous for C was 0·94 (95% CI 0·76-1·16; Table 3 ). Similar null findings were observed in models adjusting for treatment assignment, age, smoking status, history of hypertension, history of elevated cholesterol, family history of myocardial infarction before the age of 60, body mass index, presence of diabetes and frequency of exercise (Table 4) . No effect of the C148T polymorphism was observed on the separate end-points of myocardial infarction, stroke or venous thromboembolism in analyses stratified for by all traditional cardiovascular risk factors (data not shown). Risk estimates adjusted for randomized treatment assignment.
Discussion
In this large prospective study, the distribution of the C148T -fibrinogen polymorphism was similar among those who subsequently developed cardiovascular events compared with those who did not. Specifically, the adjusted relative risks associated with the presence of the T allele were 0·95 (95% CI 0·75-1·19) for all cases, 1·10 (0·83-1·45) for myocardial infarction, 0·93 (0·65-1·33) for stroke, and 0·71 (0·47-1·1) for venous thromboembolism. The Austrian Stroke Prevention group have reported that the presence of the T allele is associated with increased severity of carotid atherosclerosis, while the ECTIM study group have reported that presence of the T allele is associated with severity of coronary artery disease in a study of post-myocardial infarction patients [7, 9] . Despite these observations, our study failed to find an association between the T allele and cardiovascular events.
Several reports have confirmed that the C148T polymorphism is in complete linkage disequilibrium with the G455A polymorphism [6] [7] [8] . A recent report from the Edinburgh artery study found that the AA genotype was associated with a twofold increased risk of developing peripheral vascular disease [14] . Previous smaller casecontrol studies have reported that the AA genotype is associated with an increased risk for coronary artery disease in Chinese diabetics, and of ischaemic stroke in Japanese patients with hypertension [10, 11] . Our findings are thus at variance with these reports. These discrepancies may be explained by differences in trial design, sample size or by ethnic differences in the effect of polymorphism in the -fibrinogen promoter gene on vascular risk.
The ECTIM workers failed to find an increased risk of myocardial infarction in individuals with the A (or T) allele [13] and null data for risk of myocardial infarction have been reported by the Copenhagen City Heart Study group and the Leiden group [12, 14] . Our data support these findings and extend this observation to both stroke and venous thromboembolism. Although previous studies have confirmed that the T (or A) allele is associated with higher plasma fibrinogen levels [12, 13, 18] , our data suggest that this effect is not of sufficient magnitude to be an important determinant of cardiovascular risk.
As with any null study, consideration must be given to the possibility that our study was not sufficiently powered to detect small differences in risk. However, the number of cases evaluated in the current study is larger than in prior reports. Moreover, this study had >90% power to detect a relative risk as low as 1·45 for vascular events. In conclusion, our findings do not support the hypothesis that polymorphisms in the -fibrinogen promoter gene represent an inherited thrombotic risk factor for vascular disease.
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